Austria
International manager with more than 25 years experience in life science industries and in-depth knowledge for the life cycle management of NBE/NCE based products. Proven track record in evaluation and development of innovative products and services derived from breakthrough technology platforms. Business mentor to provide strategic advice to start-up companies for business planning, financing (PreSeed/Seed) and partnering with third parties. Key Areas: • Biologics • Medical Diagnostics • Biobanking • Translational Medicine and Companion Diagnostics • Business Development • Strategic Allicances and Innovation Management • Marketing and Sales • Financing
Human Tissue and Cell Research-Services GmbH (“HTCR-Services”) specializes in sourcing high-quality biological material for the global pharma, biotech and diagnostic industry. Through it’s network of hospitals and medical doctors, the company delivers a wide range of pathological and healthy tissues as well as matching bio-samples (e.g. PBMCs, blood). Thus enabling the discovery of new disease-related markers for molecular diagnostics and accelerating the development of new drugs and personalized treatment options. Human Tissue and Cell Research-Services GmbH is a wholly-owned subsidiary of the HTCR-Foundation and headquartered nearby the Ludwig Maximilian University Hospital, Campus Großhadern in Munich, Germany. For further information please visit: www.htcr.de and www.htcr-services.com
Biobank research infrastructure program formed by a comprehensive consortium of academic and governmental partners including JFMED, UNIZA, NOI, NURCH, MoH SR, BMC SAS and CSPV SAS. Funding provided by the EU Structural & Investment Fund (30 Mio Euro). Responsible for leading and managing business development and strategic alliances with academia, non-profit and life science organizations. BIOFORD and DIGIBIOBANK are national flagship programs in the advancement of modern medicines and therapies, enabling better understanding of the prevention, diagnosis and monitoring of a wide range of serious and life-threatening diseases – with focus on cancer and rare diseases.
Foster strategic alliances between academia, medical institutions and stakeholders from healthcare industries to promote breakthrough R&D programs such as drug target validation, clinical trial design and companion diagnostics. Appointed member of the national COVID-19 taskforce and scientific council member at the Ministry of Health. Develop national strategy for translational bio-medicine programs and establish a centralized biobank infrastructure roadmap in Slovakia with focus on oncology and rare diseases (preparation phase for EU Structural Funding Program - BIOFORD and DIGIBIOBANK).
Projects (selected activities by assignment): Austrian Institute of Technology (AIT), Expert Advisor Austria’s largest non-profit research organization is developing technological innovations, methods and solutions for industry and customers from public institutions. Served as a key member of the executive team charged with formulating strategic direction and devising business development initiatives consistent across the core units - biomarker discovery, assay development and system integration for point of care solutions. Coached high-powered business unit team with 30 FTEs and exceeding sustainable revenue growth for all departments. Lacerta Technologies GmbH, Chief Business Officer (interim position) Lacerta Technologies GmbH is a private regenerative medicine company harnessing the power of blood serum for orthobiologic solutions. Executed marketing entry of innovative bone graft products in orthopedic, dental and sports surgery use (BoneAlbuminTM). Overall responsibility for the regions sales, third party alliances and product launch in Europe. Research Studios Austria ATGLISTATIN, Start-Up Manager Directed preclinical drug discovery program for the treatment of metabolic diseases (e.g. NAFLD) in cooperation with University Graz and Technical University Graz. Coached day-to-day operation of FFG funded start-up program comprising academic team (12 FTEs) and overall budget of 1.8 Mio Euro.
Executed R&D programs for differential diagnosis and classification of patient subgroups for better disease assessment and improved response prediction. Promoted early stage biomarker projects using autoantibody based technology platform with academic and commercial institutions throughout U.S. and Europe (oncology, auto-immune diseases, neurology and cardiology). Responsible for definition of project goals with KOLs, clinical site selection, contract negotiations and biobank sourcing. Coordinated early stage biomarker R&D cooperation programs with Medical University Graz (BioPersMed) and Medical University Innsbruck (Oncotyrol).